Table 1. Patient characteristics (n=124).
| Characteristic | Value |
|---|---|
| Age (yr), median (range) | 58 (29-83) |
| FIGO stage | |
| IIIB | 6 |
| IIIC | 77 |
| IV | 41 |
| Histologic subtype, n(%) | |
| Serous | 105 (84.6) |
| Mixed adenoca. or carcinosarcoma included serous component | 10 (8.1) |
| Non-serous | 9 (7.3) |
| Method to diagnosis | |
| Laparotomy | 62 |
| Non-laparotomy | 62 |
| NACT | |
| Regimen | |
| IEP (CAP) | 43 (1) |
| TC (DC) | 78 (2) |
| CPT base | 3 |
| The no. of cycles, median (range) | 6 (2-9) |
| <5 | 32 |
| ≥5 | 92 |
| Serum CA-125 level (U/mL), median (range) | |
| Pre-NACT | 1,569.4 (13.5-24,821) |
| <1,000 | 46 |
| ≥1,000 | 77 |
| Post-NATC | 15.8 (2.3-1,965.1) |
| <16 | 61 |
| ≥16 | 58 |
| Adjuvant chemotherapy | |
| Regimen | |
| IEP (CAP) | 24 (1) |
| TC (DC) | 62 (3) |
| DP (DTX) | 21 (1) |
| Others | 7 |
| The no. of cycles, median (range) | 3 (1-8) |
CA-125, cancer antigen 125; CAP, cyclophosphamide+adriam ycin+cisplatin; CPT, irinotecan; DC, docetaxel+carboplatin; DP, docetaxel+cisplatin; DTX: docetaxel; FIGO, International Federation of Gynecology and Obstetrics; IEP, iphosphamide+epirubicin+cisplatin; NACT, neoadjuvant chemotherapy; TC, paclitaxel+carboplatin.